Navigation Links
DrugRisk Adds Latest Court Information For Januvia Lawsuits
Date:11/12/2013

New York, NY (PRWEB) November 12, 2013

The diabetes drug safety center at DrugRisk.com is alerting patients taking the medications Januvia or Janumet of new information on the site. A federal court overseeing a growing number of lawsuits alleging drugs like these caused pancreatic cancer has set the next hearing for next week. The formal case is known as In Re: Incretin-Based Therapies Products Liability Litigation, MDL 2452 (Southern District of California).

The DrugRisk Center was created to give those taking popular prescription drugs the latest product recalls, safety alerts, research and litigation news. Patients can avoid dangerous drugs, see if others are experiencing similar side effects and decide if they need legal advice.

Januvia and Janumet are popular oral diabetes medications prescribed to those with type-2 diabetes, taken twice a day to lower blood sugar levels. In recent years, they have been the best-selling drugs for pharmaceutical company Merck*.

However, DrugRisk has added studies warning of a risk of Januvia cancer. In 2011, researchers from UCLA discovered subjects given Januvia had increased rates of pancreatic cancer and thyroid cancer**. The American Medical Association recently advised diabetes drugs like these can double the risk of pancreatitis, a major risk factor for pancreatic cancer***.

Due to the number of patients who have filed a Januvia lawsuit alleging cancer, cases have been consolidated to a special federal multidistrict litigation court. (In Re: Incretin-Based Therapies Products Liability Litigation, MDL 2452, Southern District of California).

DrugRisk has added the latest court records showing 150 cases have already been filed alleging cancer from the drug class including Januvia, Byetta, Janumet or Victoza****. Judge Anthony Battaglia, who is overseeing the litigation, has scheduled the next Status Conference for November 21, 2013.

Anyone affected by cancer after taking Januvia or Janumet is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Januvia lawsuits.

For more information on the research, side effects and litigation news related to Januvia and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
**Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
***JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537
****Judicial Panel on Multidistrict Litigation, 10/17/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-October-17-2013.pdf

Read the full story at http://www.prweb.com/releases/januvia-warnings-2013/side-effects-lawsuit/prweb11327985.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
2. DrugRisk Announces Alternative to Mirena IUD May Be Available Soon
3. DrugRisk Announces Updated Information on Mirena Lawsuits
4. DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
5. DrugRisk Announces New Pradaxa Health Warning From Australia
6. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
7. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
8. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
9. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
10. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
11. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... , ... Dr. Philip Shindler, dentist in Agoura Hills , now offers ... many necessary dental treatments could require multiple appointments to complete. This could mean taking ... time. Not only could this be inconvenient, but it could also be overwhelmingly unpleasant ...
(Date:5/2/2016)... Rhinebeck, NY (PRWEB) , ... May 02, 2016 , ... ... Valley, reopened for its 2016 guest season which runs through October. Omega is offering ... talks . , “There has never been such widespread interest in or ...
(Date:5/2/2016)... ... May 02, 2016 , ... Visceral ... organs, such as the kidneys, liver and pancreas. If not properly addressed, visceral ... board-certified physician in Internal Medicine, Medical Oncology and Palliative Care, warns against the ...
(Date:5/2/2016)... ... May 02, 2016 , ... Pregnancy Awareness Month offers a great time to ... , “If you are ready to have a baby, it’s best to get started ... Babies is your Personal Conception & Pregnancy Organizer, written for women who plan on ...
(Date:5/2/2016)... ... 02, 2016 , ... Consultative health care market research firm ... and Duane Reed, VP of business development of AJMC Strategic Solutions, will be ... (PBIRG) General Meeting from May 15-17 at the Boca Raton Resort & ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
(Date:4/27/2016)... , April 27, 2016 ... titled, "Skincare Devices Market - Global Industry Analysis, Size, ... to the report, the global skincare devices market was ... anticipated to expand at a CAGR of 10.1% from ... 2023. Browse the full Skincare Devices Market (Treatment ...
Breaking Medicine Technology: